CGRP Receptor System

Calcitonin gene-related peptide (CGRP) is a 37-amino-acid neuropeptide and one of the most potent vasodilators identified in humans. Its receptor system has become the most successful therapeutic target in migraine treatment history, yielding multiple approved drugs since 2018. Understanding CGRP biology illuminates both pain neuroscience and the broader principles of peptide-receptor pharmacology.

CGRP: the peptide

CGRP exists in two isoforms produced by alternative splicing or separate gene transcription:

• Alpha-CGRP (CGRP-I) — produced by alternative RNA splicing of the calcitonin/CGRP gene (CALCA) on chromosome 11. It is predominantly expressed in the central and peripheral nervous systems, with particularly high concentrations in trigeminal ganglion neurons, dorsal root ganglia, and perivascular nerve fibers.
• Beta-CGRP (CGRP-II) — encoded by a separate gene (CALCB), also on chromosome 11. It differs from alpha-CGRP by three amino acids in humans and is mainly expressed in the enteric nervous system.

Both isoforms share similar biological activity. Alpha-CGRP is the dominant form in trigeminovascular signaling and the primary target in migraine therapeutics.

CGRP is stored in dense-core vesicles at nerve terminals and released in response to depolarization, inflammatory mediators, and activation of transient receptor potential (TRP) channels — particularly TRPV1 (the capsaicin receptor) and TRPA1.

Receptor structure: the CLR-RAMP1 complex

The CGRP receptor is not a single protein but a heteromeric complex requiring three components:

• Calcitonin receptor-like receptor (CLR) — a class B (secretin family) G-protein-coupled receptor that forms the core signaling unit. CLR alone has minimal affinity for any ligand.
• Receptor activity-modifying protein 1 (RAMP1) — a single-pass transmembrane protein that chaperones CLR to the cell surface and determines its ligand specificity. CLR paired with RAMP1 creates a high-affinity CGRP receptor. When CLR pairs with RAMP2 or RAMP3 instead, it forms receptors for adrenomedullin rather than CGRP.
• Receptor component protein (RCP) — an intracellular protein required for efficient coupling to Gs-protein signaling and cAMP production.

This modular receptor architecture is unusual in pharmacology and has important implications: therapeutic targeting can be directed at the peptide itself, the CLR-RAMP1 interface, or the receptor complex as a whole.

Upon CGRP binding, the receptor activates Gs-protein signaling, increasing intracellular cAMP through adenylyl cyclase activation. This leads to protein kinase A (PKA) activation, which mediates vasodilation through smooth muscle relaxation, modulation of ion channels, and sensitization of pain-signaling neurons.

Physiological roles

Vasodilation

CGRP is among the most potent vasodilators known, active at picomolar concentrations. It relaxes vascular smooth muscle primarily through cAMP-mediated mechanisms and partly through endothelium-dependent nitric oxide release. CGRP-containing perivascular nerves innervate cerebral, meningeal, coronary, and peripheral arteries. Upon release, CGRP causes local vasodilation that increases blood flow to the innervated tissue.

Cardiovascular protection

Despite its role in migraine, CGRP has protective cardiovascular functions. It reduces blood pressure, limits cardiac hypertrophy, protects against ischemia-reperfusion injury, and inhibits vascular smooth muscle proliferation. These protective effects raise important safety considerations for chronic CGRP blockade (discussed below).

Neurogenic inflammation

CGRP released from trigeminal nerve fibers in the meninges triggers neurogenic inflammation — a process involving vasodilation, plasma protein extravasation, and mast cell degranulation. This creates a local inflammatory environment that further sensitizes pain pathways.

Pain transmission

CGRP modulates pain signaling at multiple levels. In the periphery, it sensitizes nociceptors and enhances the effects of other pain mediators (substance P, prostaglandins). In the spinal cord dorsal horn, it facilitates glutamate release and enhances central sensitization. In the trigeminal nucleus caudalis, CGRP release contributes to the processing of head and facial pain signals.

CGRP in migraine pathophysiology

The trigeminovascular system

Migraine headache originates from activation of the trigeminovascular system — the network of trigeminal nerve fibers that innervate the meningeal blood vessels. When these fibers are activated, they release CGRP (along with substance P and pituitary adenylate cyclase-activating peptide) from their peripheral terminals in the meninges, producing vasodilation and neurogenic inflammation. Simultaneously, signals travel centrally to the trigeminal nucleus caudalis in the brainstem, where they are processed and relayed to thalamic and cortical pain centers.

Evidence for CGRP's role

Several lines of evidence implicate CGRP as a central mediator of migraine:

• Intravenous CGRP infusion provokes migraine-like headaches in migraine sufferers but not in healthy controls.
• CGRP levels in jugular venous blood rise during spontaneous migraine attacks and normalize after successful triptan treatment.
• Trigeminal ganglion neurons from migraine patients show elevated CGRP expression.
• Genetic studies have identified variants near the CGRP receptor gene (RAMP1) associated with migraine susceptibility.

Cortical spreading depression and aura

Cortical spreading depression (CSD) — the electrophysiological event underlying migraine aura — triggers CGRP release from trigeminal afferents. CSD activates meningeal nociceptors, leading to sustained trigeminal activation and the headache phase that follows aura. CGRP thus links the aura and pain phases of migraine with aura.

Therapeutic targeting of CGRP

Gepants: small molecule CGRP receptor antagonists

Gepants are orally bioavailable small molecules that competitively block the CLR-RAMP1 receptor complex. The first-generation gepants (olcegepant, telcagepant) demonstrated proof-of-concept but were limited by hepatotoxicity concerns or parenteral-only administration. Second-generation gepants overcame these limitations:

• Ubrogepant (Ubrelvy) — approved 2019 for acute migraine treatment
• Rimegepant (Nurtec ODT) — approved for both acute and preventive migraine treatment
• Atogepant (Qulipta) — approved for preventive migraine treatment
• Zavegepant (Zavzpret) — approved as a nasal spray for acute migraine

Gepants work within hours for acute treatment and reduce monthly migraine days by 3-4 days on average in prevention trials — a clinically meaningful reduction comparable to other preventive therapies.

Monoclonal antibodies targeting CGRP or its receptor

Four monoclonal antibodies have been approved for migraine prevention, each administered by subcutaneous or intravenous injection every 1-3 months:

• Erenumab (Aimovig) — the only antibody targeting the CGRP receptor (CLR-RAMP1) rather than the CGRP peptide itself. Fully human IgG2 antibody.
• Fremanezumab (Ajovy) — humanized IgG2 antibody that binds both alpha- and beta-CGRP.
• Galcanezumab (Emgality) — humanized IgG4 antibody that binds CGRP. Also approved for episodic cluster headache.
• Eptinezumab (Vyepti) — humanized IgG1 antibody administered intravenously quarterly.

These antibodies reduce monthly migraine days by approximately 3-5 days in episodic migraine and 4-7 days in chronic migraine, with meaningful proportions of patients achieving 50% or greater reduction in migraine frequency.

Safety considerations

Long-term CGRP blockade raises theoretical concerns given CGRP's cardiovascular protective functions. Monitoring data from clinical trials and post-marketing surveillance through several years of use have not identified significant cardiovascular safety signals, but the population studied has been predominantly younger migraine patients without major cardiovascular disease. Constipation is the most common side effect of CGRP-targeted therapies, consistent with CGRP's role in gut motility. Ongoing pharmacovigilance is warranted, particularly for use in patients with established cardiovascular disease, Raynaud's phenomenon, or wound healing concerns.

Future directions

Research continues into CGRP biology across conditions beyond migraine. CGRP is being investigated in cluster headache (galcanezumab is already approved), post-traumatic headache, medication-overuse headache, and fibromyalgia. The success of CGRP-targeted therapies has also reinvigorated interest in targeting other neuropeptides involved in pain — including pituitary adenylate cyclase-activating peptide (PACAP), which is emerging as the next major neuropeptide target in headache medicine.